Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MED3000
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eroxon (MED3000) is a topical gel formulation FDA approved in the US, CE marked in Europe and UKCA marked in the UK as a clinically proven topical treatment for adult men with erectile dysfunction.
Product Name : Eroxon
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 12, 2023
Lead Product(s) : MED3000
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tadalafil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the USA all clinically proven oral ED therapies are prescription-only and therefore FM71/MED3000 has the potential to be a significant innovation with its key differentiator of a rapid speed of onset and by creating a major new OTC category for ED tre...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 31, 2022
Lead Product(s) : Tadalafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MED3000
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MED3000 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Erectile Dysfunction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 02, 2021
Lead Product(s) : MED3000
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MED3000
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Futura Medical Receives US FDA Agreement for Confirmatory Clinical study, FM71 for MED3000
Details : Futura Medical has received official minutes from the US Food and Drug Administration (FDA) for MED3000, the Company’s breakthrough fast acting clinically proven treatment for erectile dysfunction.
Product Name : Eroxon
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 22, 2021
Lead Product(s) : MED3000
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetracaine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tetracaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 30, 2020
Lead Product(s) : Tetracaine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MED2005
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluating MED2005 & Nitrostat Bioavailability
Details : MED2005 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Erectile Dysfunction.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 05, 2019
Lead Product(s) : MED2005
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MED2005
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MED2005 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Erectile Dysfunction.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 23, 2019
Lead Product(s) : MED2005
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ibuprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 28, 2016
Lead Product(s) : Nitroglycerin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Glyceryl Trinitrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Erectile Dysfunction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 13, 2015
Lead Product(s) : Nitroglycerin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable